Table 2.
Serum sCD226 levels in SLE patients with each clinical manifestation.
| Clinical manifestations | n (%) | Median sCD226 levels [IQR], ng/ml | P-value | |
|---|---|---|---|---|
| Presence | Absence | |||
| Renal | 28 (48) | 0.30 [0.10–4.40] | 0.30 [0.10–2.15] | 0.863 |
| Mucocutaneous | 23 (40) | 1.56 [0.20–8.68] | 0.15 [0.10–1.29] | 0.008 |
| Hematological | 14 (24) | 3.07 [0.19–13.98] | 0.20 [0.10–1.49] | 0.041 |
| Musculoskeletal | 11 (19) | 3.36 [0.20–20.0] | 0.22 [0.10–1.84] | 0.007 |
| Neuropsychiatric | 10 (17) | 1.43 [0.32–8.47] | 0.21 [0.10–2.48] | 0.067 |
| Cardiorespiratory | 9 (16) | 3.49 [0.16–14.2] | 0.24 [0.10–1.94] | 0.146 |
Serum sCD226 levels were compared between SLE patients with each clinical manifestation and those without. The table lists the clinical manifestation that occurred in more than 10% of patients. Statistical differences among groups were evaluated using the Mann–Whitney U test.
sCD226 soluble CD226, SLE systemic lupus erythematosus, IQR interquartile range.